Clinical studies and prospective multi-center trials evaluating the TULSA-PRO procedure demonstrate high rates of targeted prostate tissue ablation and significant prostate-specific antigen (PSA) reduction, often exceeding 90% efficacy in controlling localized disease. Furthermore, clinical data highlights favorable urinary and sexual function preservation profiles compared to traditional radical surgery or radiation therapies.